Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection.

For individuals with mild-to-moderate coronavirus disease 2019 (COVID-19, caused by severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), monoclonal antibodies (MOABs) are known to prevent progression of the disease and hospitalization. Pregnant women, who are at an increased risk of severe COVID-19 infection, have been significantly underrepresented in studies for MOAB treatments, especially sotrovimab. Specifically, there has only been one case reported of a pregnant woman using sotrovimab successfully. We report a second such patient - an unvaccinated 21-year-old, COVID-19-positive, 16-week pregnant woman who was followed closely over the next 60 days post-MOAB infusion. We noted prevention in the progression of the disease and hospitalization without any fetal/pregnancy-related complications.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2022, Gupta et al.)